Bet­ting on pub­lic mar­ket de­mand for more obe­si­ty ther­a­pies, Fractyl Health files for IPO to back gene ther­a­py

A week af­ter one obe­si­ty biotech, Car­mot Ther­a­peu­tics, backed out of its IPO plans in fa­vor of a $2.7 bil­lion sale to Roche, an­oth­er an­nounced plans to go pub­lic on Nas­daq.

The com­pa­ny, Fractyl Health, had filed to go pub­lic in 2022 short­ly af­ter dis­clos­ing a $100 mil­lion Se­ries F in June 2021. But de­spite hav­ing an S-1 on file, it nev­er ac­tu­al­ly pulled the trig­ger. Now, with obe­si­ty be­com­ing the hottest thing in bio­phar­ma, it’s fi­nal­ly mak­ing the move next year, ac­cord­ing to a se­cu­ri­ties fil­ing Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER